Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

Lancet

Volumn 355, Issue 9218, 2000, Pages 1869-1874

  Aebi, S ^a   Gelber, S ^b   Castiglione Gertsch, M ^c   Gelber, R D ^b,d   Collins, J ^e   Thurlimann B ^f   Rudenstam, C M ^g   Lindtner, J ^h   Crivellari, D ⁱ   Cortes Funes, H ^j   Simoncini, E ^k   D Werner, I ^l   Coates, A S ^m   Goldhirsch, A ⁿ  

^a UNIVERSITY OF BERN   (Switzerland)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c IBCSG Coordinating Center   (Switzerland)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h INSTITUTE OF ONCOLOGY   (Slovenia)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k SPEDALI CIVILI   (Italy)

^l UNIVERSITY OF CAPE TOWN   (South Africa)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; META ANALYSIS; OVARIECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034720587     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02292-3     Document Type: Article

References (32)

1. Walker R.A., Lees E., Webb M.B., Dearing S.J. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 74:1996;1796-1800.
2. Kollias J., Elston C.W., Ellis I.O., Robertson J.F., Blamey R.W. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer. 75:1997;1318-1323.
3. Adami H.O., Malker B., Holmberg L., Persson I., Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 315:1986;559-563.
4. Chung M., Chang H.R., Bland K.I., Wanebo H.J. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 77:1996;97-103.
5. Winchester D.P., Osteen R.T., Menck H.R. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 78:1996;1838-1843.
6. Swanson G.M., Lin C.S. Survival patterns among younger women with breast cancer. the effects of age, race, stage, and treatment J Natl Cancer Inst Monogr. 16:1994;69-77.
7. Holli K., Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer. 33:1997;425-428.
8. Noyes R.D., Spanos W.J. Jr., Montague E.D. Breast cancer in women aged 30 and under. Cancer. 49:1982;1302-1307.
9. Albain K.S., Allred D.C., Clark G.M. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 16:1994;35-42.
10. Ribeiro G.G., Swindell R. The prognosis of breast carcinoma in women aged less than 40 years. Clin Radiol. 32:1981;231-236.
11. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes: Ludwig Breast Cancer Study Group. Cancer Res. 45:1985;4454-4459.
12. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer: Ludwig Breast Cancer Study Group. J Clin Oncol. 3:1985;1059-1067.
13. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle: The Ludwig Breast Cancer Study Group. N Engl J Med. 319:1988;677-683.
14. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 320:1989;491-496.
15. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients: International Breast Cancer Study Group. J Clin Oncol. 14:1996;1885-1894.
16. Castiglione Gertsch M., Johnsen C., Goldhirsch A.et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV. 15 years follow-up Ann Oncol. 5:1994;717-724.
17. Jordan V.C., Zava D.T., Eppenberger U.et al. Reliability of steroid hormone receptor assays. an international study Eur J Cancer Clin Oncol. 19:1983;357-363.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J Am Statist Assoc. 53:1958;457-481.
19. Greenwood M. The natural duration of cancer. 1926;HM Stationery Office, London.
20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
21. Cox D.R. Regression models and life-tables (with discussion). J R Stat Soc B (Methodol). 34:1972;187-220.
22. Anonymous. SAS' Technical Report P-229 SAS/STAT software: changes and enhancements, Release 6.07. Cary, NC: SAS Institute, Inc, 1992.
23. Anderson J.R., Cain K.C., Gelber R.D. Analysis of survival by tumor response. J Clin Oncol. 1:1983;710-719.
24. Pagani O., O'Neill A., Castiglione M.et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 34:1998;632-640.
25. Bonadonna G., Brusamolino E., Valagussa P.et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 294:1976;405-410.
26. Nixon A.J., Neuberg D., Hayes D.F.et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 12:1994;888-894.
27. Donegan W.L. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 47:1997;28-51.
28. Quiet C.A., Ferguson D.J., Weichselbaum R.R., Hellman S. Natural history of node-negative breast cancer. a study of 826 patients with long-term follow-up J Clin Oncol. 13:1995;1144-1151.
29. Thorpe S.M., Christensen I.J., Bruun Rasmussen B., Rose C. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer. Eur J Cancer. 29A:1993;971-977.
30. Sancho Garnier H., Delarue J.C., Mouriesse H.et al. Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? Eur J Cancer. 31a:1995;1851-1855.
31. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
32. Clarke R., Brunner N., Katzenellenbogen B.S.et al. Progression of human breast cancer cells from hormone-dependent growth both in vitro and in vivo. Proc Natl Acad Sci USA. 86:1989;3649-3653.